# reload+after+2024-01-23 07:43:25.707063
address1§Laarderhoogtweg 25
city§Amsterdam
zip§1101EB
country§Netherlands
phone§31 10 703 8441
website§https://www.argenx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC. The company is also developing ARGX-109 and ARGX-116; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; and ARGX-114, an antibody directed against the mesenchymal-epithelial transition factor receptor. In addition, its partnered product candidates include Cusatuzumab for treatment of acute myeloid leukemia; ARGX-115 for the treatment of cancer; and ARGX-112 to treat interleukin-22 receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Staten Biotechnology B.V., and Shire International GmbH. It also has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
fullTimeEmployees§843
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Timothy  Van Hauwermeiren EMBA, M.B.A., M.Sc.', 'age': 51, 'title': 'CEO & Executive Director', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 1443925, 'exercisedValue': 0, 'unexercisedValue': 47745352}, {'maxAge': 1, 'name': 'Mr. Karl  Gubitz', 'age': 53, 'title': 'Chief Financial Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 2390510}, {'maxAge': 1, 'name': 'Ms. Malini  Moorthy', 'age': 53, 'title': 'General Counsel', 'yearBorn': 1970, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Arjen  Lemmen M.Sc.', 'age': 38, 'title': 'Vice President of Corporate Development & Strategy', 'yearBorn': 1985, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 4664961}, {'maxAge': 1, 'name': 'Ms. Andria  Wilk', 'age': 49, 'title': 'Global Head of Quality', 'yearBorn': 1974, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Luc  Truyen', 'age': 58, 'title': 'Chief Medical Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Karen  Massey', 'age': 44, 'title': 'Chief Operating Officer', 'yearBorn': 1979, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Filip  Borgions', 'title': 'VP & Global Head of Technical Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Peter  Ulrichts', 'age': 43, 'title': 'Chief Scientific Officer', 'yearBorn': 1980, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Beth  DelGiacco', 'title': 'VP and Global Head of Corporate Communications & Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§4
boardRisk§2
compensationRisk§10
shareHolderRightsRisk§3
overallRisk§5
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.395
priceToSalesTrailing12Months§22.756939
currency§USD
dateShortInterest§1702598400
forwardEps§-1.48
pegRatio§0.26
exchange§NMS
quoteType§EQUITY
shortName§argenx SE
longName§argenx SE
firstTradeDateEpochUtc§1495114200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§96295c13-e973-32ba-ba5e-28b94bffe0bd
gmtOffSetMilliseconds§-18000000
targetHighPrice§612.0
targetLowPrice§346.0
targetMeanPrice§485.86
targetMedianPrice§488.0
recommendationMean§1.8
recommendationKey§buy
numberOfAnalystOpinions§21
grossMargins§0.22997
ebitdaMargins§-0.22077
trailingPegRatio§None
